Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Ahead of 2-day adcomm, FDA sounds positive on one bluebird gene therapy but questions remain for another
Endpoints
Tue, 06/7/22 - 10:08 am
FDA
Bluebird Bio
gene therapy
eli-cel
beti-cel
Even at $2M+, ICER calls bluebird's potential gene therapy for blood disorder 'superior' to standard of care
Endpoints
Thu, 06/2/22 - 10:22 am
Bluebird Bio
ICER
gene therapy
FDA
beti-cel
Go or no go? The FDA’s Amylyx dilemma
EP Vantage
Tue, 05/31/22 - 10:29 am
FDA
Amylyx
AMX0035
ALS
COVID-19
vaccines
Novavax
Moderna Therapeutics
Pfizer
Acadia Pharma
Bluebird Bio
Roche and bluebird bio settle year-long trademark case, but keep quiet on the details
Endpoints
Thu, 05/19/22 - 08:59 pm
Bluebird Bio
Roche
Spark Therapeutics
trademark
legal
ICER says bluebird bio’s $2.1m gene therapy is cost-effective
Pharmaforum
Thu, 04/14/22 - 10:36 am
Bluebird Bio
ICER
beti-cel
FDA
Feeling Blue: bluebird bio cuts staff by 30%, prepares for FDA decision
BioSpace
Tue, 04/5/22 - 11:55 am
Bluebird Bio
FDA
layoffs
restructuring
eli-cel
beti-cel
As biotech retreats, gene therapy companies retrench and redraw plans
BioPharma Dive
Thu, 03/24/22 - 08:29 pm
biotech
gene therapy
layoffs
R&D
Bluebird Bio
Allogene
uniQure
2seventy bio's honeymoon phase is over as job cuts hit 6% of staff
Fierce Biotech
Wed, 03/23/22 - 11:10 am
2seventy bio
layoffs
Bluebird Bio
bluebird says future uncertain as delays to gene therapies bite
Pharmaforum
Sun, 03/6/22 - 11:18 pm
Bluebird Bio
gene therapy
beti-cel
eli-cel
lovo-cel
Court ruling on bluebird bio’s gene therapy marketing campaign 'sparks' dismay at Roche's Spark
Fierce Pharma
Thu, 01/27/22 - 10:38 am
Bluebird Bio
gene therapy
sickle cell disease
Roche
Spark Therapeutics
No stranger to headwinds, bluebird runs into two PDUFA delays unrelated to new safety issues
Endpoints
Tue, 01/18/22 - 10:40 am
Bluebird Bio
beti-cel
eli-cel
FDA
gene therapy
beta thalassemia
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches
Fierce Pharma
Thu, 01/13/22 - 10:32 pm
JPMHC 2022
Bluebird Bio
gene therapy
sickle cell disease
beti-cel
JPM22, Day 2: Sanofi's dealmaking priorities, bluebird's gene therapy goals and more
Fierce Pharma
Tue, 01/11/22 - 11:37 am
JPMHC 2022
GSK
Sanofi
Bluebird Bio
JPM 2022: Bluebird CEO sees 'unfinished business' with Zynteglo in Europe, but scale-up needed first
Fierce Pharma
Tue, 01/11/22 - 11:31 am
Bluebird Bio
JPMHC 2022
Pharma CEOs
Europe
Zynteglo
4 Biotechs That Were Winners at ASH
Motley Fool
Mon, 01/3/22 - 10:38 am
ASH2021
Bristol Myers Squibb
Agios Pharmaceuticals
Forma Therapeutics
Bluebird Bio
sickle cell disease
Multiple Myeloma
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
Yahoo Finance
Mon, 12/20/21 - 10:54 am
Bluebird Bio
lovo-cel
gene therapy
sickle cell disease
FDA
clinical hold
clinical trials
ASH 2021 – Bluebird looks to revive Lentiglobin
EP Vantage
Mon, 12/13/21 - 10:34 am
Bluebird Bio
LentiGlobin
ASH2021
sickle cell disease
Bluebird bio may finally get a gene therapy approved in the US
Endpoints
Mon, 11/22/21 - 10:28 am
Bluebird Bio
gene therapy
FDA
Zynteglo
beta-thalassemia
priority review
With oncology spinoff done, bluebird bio moves to new digs better suited to its future
Fierce Pharma
Sun, 11/7/21 - 10:50 pm
Bluebird Bio
oncology
Cambridge
Bluebird bio completes spinout of oncology business 2seventy bio
Bizjournals
Fri, 11/5/21 - 12:00 am
Bluebird Bio
spinoff
oncology
2seventy bio
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »